The field of cancer modeling in the mouse has come a long way in the last two decades, and the pace of change is accelerating. With the recent commitments from the NIH and NCI to improve genomic tools for the mouse and to accelerate the sequencing of the mouse genome, the timing is right to scale-up cancer genetics in the mouse: with time, all major human tumor types should have one or more associated mouse models that accurately reflect the genetic and histopathological progression of the disease. The development of these mouse models requires the expert and efficient generation and analysis of genetically engineered mouse strains, as well as the generation and analysis of reagents derived from these animals. The general aim of the Core Facility CF3. Di Cristofano: Animal Models is to provide a facility in which this complex set of tasks will be optimized for 1) expert design and production; 2) efficiency; 3) cost reduction, with the following specific aims: 1) The Core Facility will generate and make available to SPORE investigators transgenic and knockout/knockin mouse strains of common interest; 2) it will assist individual components of the SPORE in the design and generation of targeting constructs as well as in the generation and characterization of the derived mouse strains; 3) it will serve as a centralized repository and breeding service for mouse strains of general use among SPORE investigators; 4) it will provide SPORE laboratories with dissected tissues, DNA, RNA and proteins from the various mouse mutants utilized by the investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092629-02
Application #
6656473
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-10
Project End
2003-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Roobol, Monique J; Carlsson, Sigrid V (2018) The ERSPC Study: Quality Takes Time and Perseverance. Clin Chem :
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467
Van Calster, Ben; Wynants, Laure; Verbeek, Jan F M et al. (2018) Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. Eur Urol 74:796-804
Shoag, Jonathan; Liu, Deli; Blattner, Mirjam et al. (2018) SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. J Clin Invest 128:381-386
Frånlund, Maria; Arnsrud Godtman, Rebecka; Carlsson, Sigrid V et al. (2018) Prostate cancer risk assessment in men with an initial P.S.A. below 3?ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial. Scand J Urol 52:256-262
Mikropoulos, Christos; Selkirk, Christina G Hutten; Saya, Sibel et al. (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118:266-276
Capogrosso, Paolo; Vertosick, Emily A; Benfante, Nicole E et al. (2018) Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. Eur Urol :
Lee, Justin K; Sjoberg, Daniel D; Miller, Mariam Imnadze et al. (2018) Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients? Eur Urol 73:33-37

Showing the most recent 10 out of 505 publications